It has been noted that estrogen affects the risk of CRC depending on the stage of CRC development; estrogen enhances ER-β expression to inhibit colon tumorigenesis in the early disease stages, whereas in the late disease stages, it stimulates ER-α expression, resulting in tumor progression [132]. This evidence concerns the gene ESR1 and colorectal carcinoma.